Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report) today and set a price target of ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart disease called pulmonary hypertension in heart failure with preserved ejection ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fell 0.25% to 19,583.83. The S&P 500 also ...

European shares were higher today. The eurozone's STOXX 600 rose 0.6%, Germany's DAX 40 gained 0.2% and France's CAC 40 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, today we look at ...

Nurses and home and health agency owners alike have told us that our AI powered app is a gamechanger. With our recent enterprise wins in this $130 Billion sector 1, we believe that we have a solution ...